Dendreon Plunges on Provenge Forecast Withdrawal

Dendreon Plunges on Provenge Forecast Withdrawal Play

Aug. 4 (Bloomberg) -- Dendreon Corp., maker of the prostate-cancer drug Provenge, fell the most in two years after the company withdrew its 2011 revenue estimate and said sales of the medicine didn’t meet projections. Shannon Pettypiece reports on Bloomberg Television's "In the Loop." (Source: Bloomberg)

Feed Most Popular

  • On Air Now

    Charlie Rose Watch Now

  • Next

    Bloomberg West

blog comments powered by Disqus